PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Pelthos Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.26+0.11 (+0.55%)
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
Pelthos Therapeutics Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Commercial operations | $15.42M | $10.67M | – | – | $0 | $0 | – | 98.8% | – |
| Research and Development operations | $183.00K | $241.00K | – | – | $0 | $0 | – | 1.2% | – |
| Segment [Member] | – | – | – | $7.41M | – | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $15.42M | $10.67M | $9.09M | $7.11M | $0 | – | – | 98.8% | – |
| License and collaboration revenues | $183.00K | $241.00K | – | – | $0 | $0 | – | 1.2% | – |
| Net product revenues | – | $10.67M | – | – | – | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Pelthos Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.